Terrestrial Bio is a biotechnology company based in Woburn, Massachusetts, working on drug delivery. Its principal asset is the Tacterra™ microarray patch (MAP) platform, a proprietary system that delivers medicines through the skin using dissolvable tips made from advanced biomaterials. The patch is designed to administer precise doses without injections, for self-administration at home or on the go.
The company positions the platform against several constraints of injectable therapies. The Tacterra™ patch is temperature-stable, removing the need for refrigeration, and it eliminates medical sharps. Terrestrial Bio reports strong clinical and in-vivo proof of concept across multiple molecules. The initial focus is on next-generation therapies, beginning with GLP-1 treatments.
The technical work spans microarray patch and dissolvable microneedle technology, transdermal delivery, biomaterials, needle-free pharmaceutical administration and temperature-stable formulation, within the biotechnology and pharmaceutical sectors and the metabolic, diabetes and obesity treatment areas. The company describes its orientation as patient-experience focused, prioritising the removal of pain and inconvenience from injectable regimens.
Terrestrial Bio operates from Woburn, Massachusetts, with a planned expansion to Allston, Massachusetts in Q4 2026. Further details on the company are published at terrestrialbio.com.
